Free Trial
→ Uranium Mine Flood That Sparked a 2006 Price Surge Returns (From Digest Publishing) (Ad)tc pixel Free LUCD Stock Alerts

Lucid Diagnostics (LUCD) Financials

Lucid Diagnostics logo
$0.48 +0.06 (+14.10%)
As of 09:44 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Lucid Diagnostics

Annual Income Statements for Lucid Diagnostics

This table shows Lucid Diagnostics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -8.28 -28 -56 -53 -53 -71
Consolidated Net Income / (Loss)		 -8.28 -28 -56 -53 -46 -58
Net Income / (Loss) Continuing Operations		 -8.28 -28 -56 -53 -46 -58
Total Pre-Tax Income 		-8.28 -28 -56 -53 -46 -58
Total Operating Income		 -8.28 -27 -56 -48 -46 -50
Total Gross Profit		 0.00 0.50 0.38 2.43 -2.75 -1.96
Total Revenue		 0.00 0.50 0.38 2.43 4.35 4.71
Operating Revenue		 0.00 0.50 0.38 2.43 4.35 4.71
Total Cost of Revenue		 0.00 0.00 0.00 0.00 7.10 6.67
Operating Cost of Revenue		 0.00 - - - 7.10 6.67
Total Operating Expenses		 8.28 28 57 51 43 48
Selling, General & Admin Expense		 1.53 13 24 19 20 24
Marketing Expense		 1.31 5.26 16 16 16 18
Research & Development Expense		 5.44 9.30 11 7.25 5.99 5.68
Amortization Expense		 - 0.00 1.65 2.02 0.69 0.42
Total Other Income / (Expense), net		 0.00 -0.66 0.16 -4.20 0.52 -8.37
Interest Expense		 0.00 0.66 0.01 0.44 5.19 0.02
Interest & Investment Income		 - - 0.09 0.42 0.32 0.39
Other Income / (Expense), net		 - - 0.08 -4.18 5.39 -8.73
Income Tax Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Preferred Stock Dividends Declared		 - - - 0.00 7.50 13
Basic Earnings per Share		 ($0.59) ($1.51) ($1.55) ($1.26) ($1.05) ($0.69)
Weighted Average Basic Shares Outstanding		 14.11M 18.60M 36.17M 41.76M 50.52M 101.95M
Weighted Average Diluted Shares Outstanding		 14.11M 18.60M 36.17M 41.76M 90.75M 176.95M
Weighted Average Basic & Diluted Shares Outstanding		 14.11M 18.60M 43.39M 48.24M 90.75M 176.95M

Quarterly Income Statements for Lucid Diagnostics

This table shows Lucid Diagnostics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -18 -11 -12 -12 -36 -7.89 -10 -16 -24 -15 -6.68
Consolidated Net Income / (Loss)		 -11 -11 -12 -12 -27 -4.44 -10 -16 -14 -12 -6.68
Net Income / (Loss) Continuing Operations		 -11 -11 -12 -12 -27 -4.44 -10 -16 -14 -12 -6.68
Total Pre-Tax Income 		-11 -11 -12 -12 -27 -4.44 -10 -16 -14 -12 -6.68
Total Operating Income		 -11 -11 -12 -12 -12 -11 -12 -14 -12 -13 -12
Total Gross Profit		 1.00 0.98 1.17 1.20 -0.72 -0.40 -0.49 -5.17 -0.37 0.03 -0.20
Total Revenue		 1.00 0.98 1.17 1.20 0.83 1.16 1.21 1.50 1.26 1.47 1.20
Operating Revenue		 1.00 0.98 1.17 1.20 0.83 1.16 1.21 1.50 1.26 1.47 1.20
Total Cost of Revenue		 0.00 0.00 0.00 - 1.55 1.56 1.70 6.67 1.63 1.45 1.40
Operating Cost of Revenue		 - - - - 1.55 1.56 1.70 - 1.63 1.45 1.40
Total Operating Expenses		 12 12 13 14 12 11 11 8.84 12 13 12
Selling, General & Admin Expense		 4.07 4.87 5.36 5.86 6.16 5.62 5.61 6.48 5.43 5.76 5.54
Marketing Expense		 4.19 4.21 4.06 4.00 4.07 4.01 4.29 5.34 5.00 5.78 5.25
Research & Development Expense		 1.50 1.37 1.67 1.45 1.43 1.26 1.27 1.72 1.21 1.19 1.18
Amortization Expense		 0.37 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11
Total Other Income / (Expense), net		 0.18 0.19 -0.68 0.83 -14 6.95 1.36 -2.41 -1.80 1.11 5.60
Interest Expense		 0.18 0.52 0.44 4.06 0.01 0.01 0.00 0.01 0.01 0.00 0.00
Interest & Investment Income		 0.07 0.11 0.08 0.07 0.07 0.11 0.10 0.11 0.07 0.08 0.06
Other Income / (Expense), net		 0.29 0.60 -0.32 4.83 -14 6.84 1.26 -2.52 -1.86 1.04 5.54
Income Tax Expense		 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Preferred Stock Dividends Declared		 7.50 0.00 0.00 - 9.11 3.45 0.00 - 9.72 3.03 0.00
Basic Earnings per Share		 ($0.40) ($0.23) ($0.25) ($0.17) ($0.52) ($0.08) ($0.10) $0.01 ($0.17) ($0.08) ($0.03)
Weighted Average Basic Shares Outstanding		 45.01M 48.21M 50.37M 50.52M 68.80M 98.99M 108.18M 101.95M 140.10M 183.12M 190.94M
Weighted Average Diluted Shares Outstanding		 45.01M 48.21M 50.37M 50.52M 108.19M 108.48M 137.68M 176.95M 203.07M 203.24M 206.98M
Weighted Average Basic & Diluted Shares Outstanding		 52.11M 53.99M 59.34M 90.75M 108.19M 108.48M 137.68M 176.95M 203.07M 203.24M 206.98M

Annual Cash Flow Statements for Lucid Diagnostics

This table details how cash moves in and out of Lucid Diagnostics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -0.05 54 -31 -3.58 3.46 12
Net Cash From Operating Activities		 -5.63 -18 -30 -33 -44 -46
Net Cash From Continuing Operating Activities		 -5.63 -18 -30 -33 -44 -46
Net Income / (Loss) Continuing Operations		 -8.28 -28 -56 -53 -46 -58
Consolidated Net Income / (Loss)		 -8.28 -28 -56 -53 -46 -58
Depreciation Expense		 0.00 0.00 1.94 2.50 1.17 0.87
Non-Cash Adjustments To Reconcile Net Income		 2.43 9.60 16 12 -0.37 13
Changes in Operating Assets and Liabilities, net		 0.22 0.81 8.91 5.68 0.24 -2.82
Net Cash From Investing Activities		 0.00 -0.86 -4.11 -0.22 -0.65 -0.20
Net Cash From Continuing Investing Activities		 0.00 -0.86 -4.11 -0.22 -0.65 -0.20
Purchase of Property, Plant & Equipment		 0.00 0.00 -3.20 - -0.30 -0.20
Acquisitions		 - - - 0.00 -0.35 0.00
Net Cash From Financing Activities		 5.58 72 2.61 29 48 59
Net Cash From Continuing Financing Activities		 5.58 72 2.61 29 48 59
Repayment of Debt		 - - - 0.00 -3.62 0.00
Issuance of Debt		 5.58 7.74 0.00 10 22 0.36
Issuance of Preferred Equity		 - - 0.00 19 30 0.00
Issuance of Common Equity		 0.00 70 1.92 0.55 0.45 59
Other Financing Activities, net		 0.01 0.00 0.70 0.28 0.00 0.02

Quarterly Cash Flow Statements for Lucid Diagnostics

This table details how cash moves in and out of Lucid Diagnostics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents		 5.87 0.15 -10 7.87 2.88 5.89 16 -13 -6.83 5.53 -15
Net Cash From Operating Activities		 -13 -11 -10 -9.87 -12 -11 -11 -13 -12 -11 -16
Net Cash From Continuing Operating Activities		 -13 -11 -10 -9.97 -13 -11 -11 -13 -12 -11 -16
Net Income / (Loss) Continuing Operations		 -11 -11 -12 -12 -27 -4.44 -10 -16 -14 -12 -6.68
Consolidated Net Income / (Loss)		 -11 -11 -12 -12 -27 -4.44 -10 -16 -14 -12 -6.68
Depreciation Expense		 0.50 0.23 0.22 0.22 0.22 0.22 0.22 0.21 0.22 0.22 0.23
Non-Cash Adjustments To Reconcile Net Income		 0.83 1.21 2.12 0.40 16 -5.62 -0.02 3.54 3.29 0.68 -9.33
Changes in Operating Assets and Liabilities, net		 -3.33 -1.91 -0.14 0.95 -1.37 -0.71 -0.69 -0.06 -1.70 -0.52 0.23
Net Cash From Investing Activities		 -0.04 - -0.35 -0.26 -0.09 -0.03 -0.03 -0.05 -0.22 -0.02 -0.02
Net Cash From Continuing Investing Activities		 -0.04 - -0.35 -0.26 -0.09 -0.03 -0.03 -0.05 -0.22 -0.02 -0.02
Purchase of Property, Plant & Equipment		 - - - - -0.09 - - - -0.22 -0.02 -0.02
Net Cash From Financing Activities		 19 12 0.09 18 15 16 27 0.00 5.49 17 0.16
Net Cash From Continuing Financing Activities		 19 12 0.09 18 15 16 27 0.00 5.49 17 0.16
Issuance of Common Equity		 0.35 - 0.09 - 15 16 27 0.27 5.48 17 0.16
Other Financing Activities, net		 0.00 - - - 0.00 0.28 0.00 -0.27 0.00 0.00 -0.00

Annual Balance Sheets for Lucid Diagnostics

This table presents Lucid Diagnostics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 2.20 59 33 27 31 40
Total Current Assets		 1.44 57 24 22 25 37
Cash & Equivalents		 0.11 54 22 19 22 35
Accounts Receivable		 0.00 0.20 0.02 0.05 0.05 0.64
Inventories, net		 - - 0.11 0.28 0.34 0.35
Prepaid Expenses		 1.33 3.45 1.75 2.85 2.40 1.77
Plant, Property, & Equipment, net		 0.00 0.97 1.59 1.33 1.06 0.81
Total Noncurrent Assets		 0.76 0.73 6.56 3.86 4.51 2.17
Intangible Assets		 - 0.00 3.45 1.42 0.74 0.32
Other Noncurrent Operating Assets		 0.76 0.73 3.12 2.44 3.77 1.85
Total Liabilities & Shareholders' Equity		 2.20 59 33 27 31 40
Total Liabilities		 16 4.26 9.46 30 25 30
Total Current Liabilities		 2.45 4.26 8.43 29 24 29
Short-Term Debt		 - - 0.00 14 19 24
Accounts Payable		 2.06 2.60 2.50 4.99 1.24 0.97
Accrued Expenses		 0.39 - - - 2.83 2.72
Other Current Liabilities		 - 1.66 5.92 10 0.85 0.89
Total Noncurrent Liabilities		 13 0.00 1.04 0.20 1.80 0.93
Other Noncurrent Operating Liabilities		 13 0.00 1.04 0.20 1.80 0.93
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -14 55 23 -2.31 5.39 11
Total Preferred & Common Equity		 -14 55 23 -2.31 5.39 11
Preferred Stock		 0.00 0.00 0.00 19 54 54
Total Common Equity		 -14 55 23 -21 -49 -43
Common Stock		 0.31 97 121 130 155 231
Retained Earnings		 -14 -42 -98 -151 -204 -274

Quarterly Balance Sheets for Lucid Diagnostics

This table presents Lucid Diagnostics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets		 33 32 34 23 33 39 53 34 39 28
Total Current Assets		 27 28 28 17 28 34 50 31 37 26
Cash & Equivalents		 24 25 25 14 25 31 47 28 33 18
Accounts Receivable		 0.02 0.05 0.16 0.04 0.06 0.37 0.55 0.69 1.09 0.84
Inventories, net		 - 0.41 0.68 0.65 0.48 0.51 0.49 0.47 0.48 0.52
Prepaid Expenses		 3.23 2.36 2.18 1.65 1.75 1.83 1.47 2.33 1.65 6.61
Plant, Property, & Equipment, net		 1.28 1.24 1.05 0.94 1.04 0.95 0.86 0.91 0.81 0.71
Total Noncurrent Assets		 4.66 3.22 5.12 4.83 4.22 3.89 2.49 1.81 1.51 1.19
Intangible Assets		 1.93 1.05 0.95 0.84 0.63 0.53 0.42 0.21 0.11 0.00
Other Noncurrent Operating Assets		 2.73 2.17 4.17 3.99 3.59 3.36 2.07 1.60 1.41 1.19
Total Liabilities & Shareholders' Equity		 33 32 34 23 33 39 53 34 39 28
Total Liabilities		 31 20 18 16 38 31 27 30 28 22
Total Current Liabilities		 30 20 16 14 37 29 26 29 28 22
Short-Term Debt		 14 13 11 10 33 25 22 25 24 17
Accounts Payable		 4.32 4.11 3.63 3.14 2.90 3.26 3.03 1.08 0.67 1.01
Accrued Expenses		 - - - - - - - 2.20 2.44 2.43
Other Current Liabilities		 11 2.73 1.15 0.91 0.87 0.87 0.88 0.91 0.91 0.91
Total Noncurrent Liabilities		 0.46 0.18 2.15 2.01 1.60 1.38 1.16 0.70 0.50 0.28
Capital Lease Obligations		 - - - - - - - - - 0.28
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 2.56 12 16 6.34 -5.38 7.86 26 4.00 11 5.93
Total Preferred & Common Equity		 2.56 12 16 6.34 -5.38 7.86 26 4.00 11 5.93
Preferred Stock		 14 44 56 56 54 54 54 10 0.00 0.00
Total Common Equity		 -11 -32 -40 -50 -60 -47 -28 -6.13 11 5.93
Common Stock		 129 136 140 143 180 201 230 292 324 325
Retained Earnings		 -140 -169 -180 -192 -240 -248 -258 -298 -313 -319

Annual Metrics And Ratios for Lucid Diagnostics

This table displays calculated financial ratios and metrics derived from Lucid Diagnostics' official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 36,808,647.00 39,108,245.00 44,667,304.00 - 137,683,002.00
DEI Adjusted Shares Outstanding		 0.00 36,808,647.00 39,108,245.00 44,667,304.00 - 137,683,002.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -0.76 -1.44 -1.18 - -0.51
Growth Metrics		 - - - - - -
Revenue Growth		 0.00% 0.00% -24.60% 544.03% 79.00% 8.28%
EBITDA Growth		 0.00% -231.10% -97.83% 7.50% 21.28% -45.61%
EBIT Growth		 0.00% -231.15% -104.86% 6.24% 22.80% -43.57%
NOPAT Growth		 0.00% -231.15% -105.15% 13.81% 5.01% -7.79%
Net Income Growth		 0.00% -239.11% -100.05% 6.24% 13.55% -27.41%
EPS Growth		 0.00% 0.00% 0.00% 18.71% 16.67% 0.00%
Operating Cash Flow Growth		 0.00% -213.87% -68.02% -10.55% -34.50% -5.31%
Free Cash Flow Firm Growth		 0.00% 0.00% -14.63% 32.83% -57.53% 18.92%
Invested Capital Growth		 0.00% 107.95% -47.09% -1,366.49% 122.50% -85.85%
Revenue Q/Q Growth		 0.00% 0.00% -33.27% 61.87% 3.75% 6.98%
EBITDA Q/Q Growth		 0.00% 0.00% -5.94% 7.58% 6.79% -18.53%
EBIT Q/Q Growth		 0.00% 0.00% -6.96% 7.22% 7.47% -18.18%
NOPAT Q/Q Growth		 0.00% 0.00% -7.11% 6.77% -2.04% -3.41%
Net Income Q/Q Growth		 0.00% 0.00% -6.89% 7.22% -1.59% -8.87%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 7.08% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% -86.63% 15.92% -21.11% 0.24% -6.18%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 9.35% -1.19% -3.06%
Invested Capital Q/Q Growth		 0.00% 0.00% -4.34% -3.61% -20.30% -71.23%
Profitability Metrics		 - - - - - -
Gross Margin		 0.00% 100.00% 100.00% 100.00% 100.00% -41.73%
EBITDA Margin		 0.00% -5,483.00% -14,385.94% -2,066.19% -908.67% -1,221.89%
Operating Margin		 0.00% -5,483.80% -14,920.69% -1,996.79% -1,059.64% -1,054.82%
EBIT Margin		 0.00% -5,483.80% -14,899.47% -2,169.11% -935.53% -1,240.42%
Profit (Net Income) Margin		 0.00% -5,615.60% -14,899.47% -2,169.11% -1,047.61% -1,232.68%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.00% 102.40% 100.00% 100.00% 111.98% 99.38%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% -4,755.52% 0.00% 0.00% -3,728.33%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% -4,711.40% 0.00% 0.00% -3,406.65%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 4,611.09% 0.00% 0.00% 3,017.72%
Return on Equity (ROE)		 61.25% -136.23% -144.42% -507.97% -2,956.43% -710.60%
Cash Return on Invested Capital (CROIC)		 0.00% -3,130.68% -4,693.93% 0.00% -2,518.46% -3,577.90%
Operating Return on Assets (OROA)		 0.00% -89.61% -122.77% -176.20% -140.24% -164.06%
Return on Assets (ROA)		 0.00% -91.77% -122.77% -176.20% -157.04% -163.04%
Return on Common Equity (ROCE)		 61.25% -136.23% -144.42% -51.71% 67,157.00% 4,020.06%
Return on Equity Simple (ROE_SIMPLE)		 61.25% -51.29% -243.72% 2,278.93% -844.54% 0.00%
Net Operating Profit after Tax (NOPAT)		 -5.80 -19 -39 -34 -32 -35
NOPAT Margin		 0.00% -3,838.66% -10,444.48% -1,397.75% -741.75% -738.38%
Net Nonoperating Expense Percent (NNEP)		 -2,237.84% -33.05% -44.12% -136.61% -305.44% -321.68%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -291.58% -134.37% -99.46%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 141.73%
SG&A Expenses to Revenue		 0.00% 2,555.60% 6,359.15% 793.00% 463.78% 507.16%
R&D to Revenue		 0.00% 1,859.20% 2,985.94% 298.68% 137.87% 120.65%
Operating Expenses to Revenue		 0.00% 5,583.80% 15,020.69% 2,096.79% 1,159.64% 1,013.09%
Earnings before Interest and Taxes (EBIT)		 -8.28 -27 -56 -53 -41 -58
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -8.28 -27 -54 -50 -39 -58
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 0.00 3.61 2.31 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 0.00 3.61 2.71 0.00 0.00 0.00
Price to Revenue (P/Rev)		 0.00 395.32 141.08 25.94 11.18 63.74
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 132.97 53.60 0.00 60.77 1,487.14
Enterprise Value to Revenue (EV/Rev)		 0.00 288.01 81.47 31.57 22.84 73.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 0.00 0.00 0.00 -6.04 3.45 2.19
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.01 -1.30 -0.98 -1.32 -2.83 -0.89
Leverage Ratio		 -0.16 1.48 1.18 2.88 18.83 4.36
Compound Leverage Factor		 -0.16 1.52 1.18 2.88 21.08 4.33
Debt to Total Capital		 0.00% 0.00% 0.00% 119.86% 77.53% 68.70%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 119.86% 77.53% 68.70%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 160.02% 226.83% 155.35%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% -179.88% -204.36% -124.05%
Debt to EBITDA		 0.00 0.00 0.00 -0.28 -0.47 -0.42
Net Debt to EBITDA		 0.00 0.00 0.00 0.10 0.10 0.19
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 -0.41 -0.58 -0.69
Net Debt to NOPAT		 0.00 0.00 0.00 0.15 0.12 0.31
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -19.15 26.40 -5.95 -13.07 -12.30 -7.78
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 89.82% 2,371.56% 665.73%
Liquidity Ratios		 - - - - - -
Current Ratio		 0.59 13.45 2.89 0.75 1.07 1.31
Quick Ratio		 0.05 12.64 2.67 0.64 0.95 1.24
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -34 -39 -26 -41 -33
Operating Cash Flow to CapEx		 0.00% 0.00% -927.66% 0.00% 0.00% -23,596.45%
Free Cash Flow to Firm to Interest Expense		 0.00 -51.45 -4,858.21 -59.07 -7.92 -1,515.73
Operating Cash Flow to Interest Expense		 0.00 -26.81 -3,710.63 -74.25 -8.50 -2,112.95
Operating Cash Flow Less CapEx to Interest Expense		 0.00 -26.81 -4,110.63 -74.25 -8.50 -2,121.91
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.00 0.02 0.01 0.08 0.15 0.13
Accounts Receivable Turnover		 0.00 0.00 3.47 78.32 96.58 13.68
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 19.22
Fixed Asset Turnover		 0.00 0.00 0.29 1.66 3.63 5.03
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 6.03
Days Sales Outstanding (DSO)		 0.00 0.00 105.05 4.66 3.78 26.68
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 18.99
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 60.50
Cash Conversion Cycle (CCC)		 0.00 0.00 105.05 4.66 3.78 -14.83
Capital & Investment Metrics		 - - - - - -
Invested Capital		 -14 1.08 0.57 -7.26 1.63 0.23
Invested Capital Turnover		 0.00 -0.08 0.46 -0.73 -1.55 5.05
Increase / (Decrease) in Invested Capital		 0.00 15 -0.51 -7.83 8.89 -1.40
Enterprise Value (EV)		 70 144 31 77 99 344
Market Capitalization		 70 198 53 63 49 300
Book Value per Share		 ($0.96) $1.49 $0.59 ($0.47) ($0.83) ($0.16)
Tangible Book Value per Share		 ($0.96) $1.49 $0.50 ($0.50) ($0.84) ($0.16)
Total Capital		 -14 55 23 12 24 35
Total Debt		 0.00 0.00 0.00 14 19 24
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -0.11 -54 -22 -4.95 -3.76 -11
Capital Expenditures (CapEx)		 0.00 0.00 3.20 0.00 0.00 0.20
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.12 -0.61 -6.54 -12 -2.13 -1.82
Debt-free Net Working Capital (DFNWC)		 -1.01 53 16 6.64 20 33
Net Working Capital (NWC)		 -1.01 53 16 -7.31 1.62 8.89
Net Nonoperating Expense (NNE)		 2.48 8.88 17 19 13 23
Net Nonoperating Obligations (NNO)		 -0.11 -54 -22 -4.95 -3.76 -11
Total Depreciation and Amortization (D&A)		 0.00 0.00 1.94 2.50 1.17 0.87
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -122.60% -1,735.54% -504.74% -49.10% -38.65%
Debt-free Net Working Capital to Revenue		 0.00% 10,608.60% 4,225.73% 273.52% 465.35% 698.81%
Net Working Capital to Revenue		 0.00% 10,608.60% 4,225.73% -301.03% 37.37% 188.82%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($1.51) ($1.55) ($1.26) ($1.05) ($0.69)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 37.43M 36.17M 41.76M 50.52M 101.95M
Adjusted Diluted Earnings per Share		 $0.00 ($1.51) $0.00 ($1.26) ($1.05) $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 37.43M 43.39M 41.76M 50.52M 176.95M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($1.51) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 18.60M 43.39M 48.24M 90.75M 176.95M
Normalized Net Operating Profit after Tax (NOPAT)		 -5.80 -19 -39 -34 -32 -35
Normalized NOPAT Margin		 0.00% -3,838.66% -10,444.48% -1,397.75% -741.75% -738.38%
Pre Tax Income Margin		 0.00% -5,615.60% -14,899.47% -2,169.11% -1,047.61% -1,232.68%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 0.00 -41.61 -7,021.38 -119.15 -7.83 -2,653.36
NOPAT to Interest Expense		 0.00 -29.12 -4,921.96 -76.78 -6.21 -1,579.45
EBIT Less CapEx to Interest Expense		 0.00 -41.61 -7,421.38 -119.15 -7.83 -2,662.32
NOPAT Less CapEx to Interest Expense		 0.00 -29.12 -5,321.96 -76.78 -6.21 -1,588.41
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Lucid Diagnostics

This table displays calculated financial ratios and metrics derived from Lucid Diagnostics' official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding		 48,244,798.00 52,114,353.00 53,990,294.00 - 90,958,695.00 108,411,028.00 137,508,926.00 137,683,002.00 176,945,972.00 203,066,783.00 203,243,970.00
DEI Adjusted Shares Outstanding		 48,244,798.00 52,114,353.00 53,990,294.00 - 90,958,695.00 108,411,028.00 137,508,926.00 137,683,002.00 176,945,972.00 203,066,783.00 203,243,970.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.38 -0.21 -0.23 - -0.40 -0.07 -0.08 -0.12 -0.13 -0.07 -0.03
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 124.44% 513.84% 49.68% 15.10% -17.28% 19.16% 3.33% 25.65% 51.69% 26.74% -0.66%
EBITDA Growth		 36.04% 3.57% 13.12% 28.18% -167.44% 58.31% 13.76% -122.73% 48.58% -166.98% 36.65%
EBIT Growth		 35.37% 6.92% 15.43% 30.30% -156.79% 57.11% 13.47% -118.95% 48.18% -158.86% 35.83%
NOPAT Growth		 24.62% 3.38% -5.09% -8.04% -15.71% -1.72% -0.56% -13.22% 2.99% -12.45% -4.40%
Net Income Growth		 34.68% 3.30% 12.93% -6.57% -153.56% 59.66% 15.96% -40.94% 48.31% -163.28% 35.78%
EPS Growth		 0.00% 14.81% 26.47% 32.00% 0.00% 65.22% 60.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Growth		 -77.13% -65.52% -15.88% 1.08% 1.17% 8.13% -7.06% -27.42% 2.92% -7.09% -42.75%
Free Cash Flow Firm Growth		 -20.63% -1,290.76% -9,138.37% -9,280.97% -1.19% 51.52% 59.48% 52.11% 28.54% -2.53% -90.52%
Invested Capital Growth		 109.76% 138.36% 129.25% 122.50% 724.53% -9.74% -60.81% -85.85% -39.41% -49.83% 587.17%
Revenue Q/Q Growth		 -3.75% -2.50% 20.08% 2.13% -30.83% 40.46% 4.13% 24.19% -16.49% 17.36% -18.39%
EBITDA Q/Q Growth		 1.97% -3.64% -13.87% 37.92% -265.06% 83.81% -135.52% -60.33% 15.73% 16.11% 43.57%
EBIT Q/Q Growth		 3.04% -0.88% -13.43% 37.18% -257.25% 83.12% -128.86% -58.95% 15.45% 15.84% 42.73%
NOPAT Q/Q Growth		 5.77% -3.71% -4.49% -5.81% -0.91% 8.83% -3.29% -19.14% 13.53% -5.67% 4.10%
Net Income Q/Q Growth		 2.01% -3.70% -12.41% 6.71% -133.15% 83.50% -134.22% -56.45% 14.49% 15.98% 42.87%
EPS Q/Q Growth		 -60.00% 42.50% -8.70% 32.00% 0.00% 84.62% -25.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 -26.39% 8.96% 11.38% 2.99% -26.28% 15.37% -3.26% -15.47% 3.79% 6.64% -37.65%
Free Cash Flow Firm Q/Q Growth		 -5,530.89% -51.70% -7.86% -1.82% 39.26% 27.32% 9.85% -20.32% 9.35% -4.28% -67.51%
Invested Capital Q/Q Growth		 103.65% 752.45% -9.30% -20.30% 33.80% -6.68% -60.62% -71.23% 473.16% -22.73% 439.39%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% -87.32% 100.00% 100.00% -343.48% -29.38% 1.97% -16.71%
EBITDA Margin		 -999.00% -1,061.89% -1,006.91% -612.03% -3,229.95% -371.54% -840.38% -1,084.91% -1,094.82% -782.63% -541.15%
Operating Margin		 -1,078.12% -1,146.72% -997.78% -1,033.75% -1,508.09% -978.85% -971.02% -931.52% -964.49% -868.45% -1,020.45%
EBIT Margin		 -1,049.05% -1,085.35% -1,025.26% -630.58% -3,256.64% -390.63% -858.55% -1,098.80% -1,112.50% -797.83% -559.85%
Profit (Net Income) Margin		 -1,060.14% -1,127.56% -1,055.55% -964.16% -3,249.76% -381.69% -858.55% -1,081.52% -1,107.40% -792.88% -555.03%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 101.06% 103.89% 102.95% 152.90% 99.79% 97.71% 100.00% 98.43% 99.54% 99.38% 99.14%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% -3,596.15% -1,390.16% -2,096.81% -3,292.49% -1,975.60% -2,162.06% -1,228.83%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% -2,702.76% -1,426.28% -2,082.04% -3,203.17% -2,197.83% -2,127.39% -1,243.89%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 1,686.69% 1,169.15% 1,897.47% 2,837.48% 7,798.55% 1,780.69% 996.38%
Return on Equity (ROE)		 -255.60% -300.52% -1,007.83% -2,956.43% -1,909.47% -221.00% -199.34% -455.01% 5,822.96% -381.37% -232.45%
Cash Return on Invested Capital (CROIC)		 -13,000.34% -1,741.63% -1,983.64% -2,518.46% -2,885.13% -1,551.29% -2,269.06% -3,577.90% -1,916.55% -2,251.00% -1,283.21%
Operating Return on Assets (OROA)		 -77.10% -107.69% -153.82% -94.52% -419.17% -46.80% -99.66% -145.33% -170.81% -111.94% -75.11%
Return on Assets (ROA)		 -77.92% -111.87% -158.36% -144.53% -418.28% -45.73% -99.66% -143.05% -170.03% -111.25% -74.46%
Return on Common Equity (ROCE)		 146.62% 372.56% 6,872.57% 67,157.00% 27,010.59% 801.82% 483.39% 2,574.13% 278,799.96% 723.19% 164.69%
Return on Equity Simple (ROE_SIMPLE)		 -395.42% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -7.55 -7.83 -8.19 -8.66 -8.74 -7.97 -8.23 -9.81 -8.48 -8.96 -8.59
NOPAT Margin		 -754.69% -802.70% -698.45% -723.63% -1,055.66% -685.19% -679.71% -652.06% -675.14% -607.92% -714.31%
Net Nonoperating Expense Percent (NNEP)		 -15.58% -18.28% -60.44% -66.16% -893.39% 36.12% -14.77% -89.32% 222.24% -34.67% 15.06%
Return On Investment Capital (ROIC_SIMPLE)		 -30.18% -28.83% -49.50% -36.10% -31.87% -24.03% -17.10% -28.07% -29.04% -26.03% -36.55%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 187.32% 0.00% 0.00% 443.48% 129.38% 98.03% 116.71%
SG&A Expenses to Revenue		 406.59% 498.67% 456.91% 489.89% 744.20% 482.98% 462.84% 431.05% 432.48% 390.57% 460.18%
R&D to Revenue		 149.95% 140.57% 142.15% 121.39% 172.46% 107.91% 105.04% 114.56% 96.02% 80.87% 98.25%
Operating Expenses to Revenue		 1,178.12% 1,246.72% 1,097.78% 1,133.75% 1,420.77% 1,078.85% 1,071.02% 588.03% 935.11% 870.42% 1,003.74%
Earnings before Interest and Taxes (EBIT)		 -11 -11 -12 -7.55 -27 -4.54 -10 -17 -14 -12 -6.74
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -10 -10 -12 -7.33 -27 -4.32 -10 -16 -14 -12 -6.51
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 19.88 25.73
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 20.08 25.73
Price to Revenue (P/Rev)		 13.10 11.25 10.50 11.18 32.40 52.53 49.80 63.74 39.64 39.90 28.07
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 270.68 37.60 46.67 60.77 90.25 136.15 309.21 1,487.14 159.32 202.72 27.59
Enterprise Value to Revenue (EV/Rev)		 24.05 22.35 22.83 22.84 47.26 63.67 56.44 73.00 41.09 38.09 28.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 1.10 0.70 1.61 3.45 -6.10 3.22 0.86 2.19 6.30 2.15 2.96
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.05
Financial Leverage		 -1.07 -1.12 -1.56 -2.83 -0.62 -0.82 -0.91 -0.89 -3.55 -0.84 -0.80
Leverage Ratio		 2.21 2.47 6.28 18.83 9.95 3.05 2.36 4.36 -48.57 4.13 2.55
Compound Leverage Factor		 2.23 2.56 6.46 28.79 9.93 2.98 2.36 4.29 -48.34 4.11 2.53
Debt to Total Capital		 52.49% 41.21% 61.68% 77.53% 119.61% 76.29% 46.33% 68.70% 86.30% 68.26% 74.77%
Short-Term Debt to Total Capital		 52.49% 41.21% 61.68% 77.53% 119.61% 76.29% 46.33% 68.70% 86.30% 68.26% 73.58%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1.19%
Preferred Equity to Total Capital		 176.90% 205.74% 338.12% 226.83% 198.44% 164.10% 112.75% 155.35% 34.71% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -129.39% -146.95% -299.80% -204.36% -218.05% -140.39% -59.08% -124.05% -21.01% 31.74% 25.23%
Debt to EBITDA		 -0.30 -0.25 -0.24 -0.47 -0.58 -0.50 -0.46 -0.42 -0.57 -0.45 -0.37
Net Debt to EBITDA		 0.26 0.31 0.10 0.10 -0.13 0.12 0.52 0.19 0.06 0.19 0.01
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.01
Debt to NOPAT		 -0.42 -0.36 -0.32 -0.58 -0.98 -0.75 -0.66 -0.69 -0.73 -0.66 -0.49
Net Debt to NOPAT		 0.37 0.44 0.14 0.12 -0.23 0.17 0.74 0.31 0.08 0.28 0.01
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.01
Altman Z-Score		 -6.92 -6.46 -11.72 -8.74 -11.03 -4.64 -2.02 -4.37 -9.31 -7.16 -12.29
Noncontrolling Interest Sharing Ratio		 157.36% 223.97% 781.92% 2,371.56% 1,514.56% 462.81% 342.50% 665.73% -4,687.94% 289.63% 170.85%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.38 1.75 1.18 1.07 0.75 1.15 1.90 1.31 1.07 1.33 1.20
Quick Ratio		 1.24 1.57 1.02 0.95 0.69 1.07 1.83 1.24 0.97 1.25 0.87
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -11 -16 -17 -18 -11 -7.75 -6.99 -8.41 -7.62 -7.94 -13
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% -13,403.23% 0.00% 0.00% 0.00% -5,628.37% -53,795.24% -91,470.59%
Free Cash Flow to Firm to Interest Expense		 -58.86 -30.79 -39.54 -4.32 -1,184.54 -1,291.47 -3,492.65 -1,681.00 -1,269.80 -1,986.18 -13,308.20
Operating Cash Flow to Interest Expense		 -70.46 -22.12 -23.34 -2.43 -1,385.00 -1,758.17 -5,446.50 -2,515.60 -2,016.83 -2,824.25 -15,550.00
Operating Cash Flow Less CapEx to Interest Expense		 -70.46 -22.12 -23.34 -2.43 -1,395.33 -1,758.17 -5,446.50 -2,515.60 -2,052.67 -2,829.50 -15,567.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.07 0.10 0.15 0.15 0.13 0.12 0.12 0.13 0.15 0.14 0.13
Accounts Receivable Turnover		 78.50 38.97 139.63 96.58 75.87 16.36 14.94 13.68 13.69 7.45 7.81
Inventory Turnover		 0.00 0.00 0.00 0.00 19.35 0.00 0.00 19.22 14.15 13.40 12.59
Fixed Asset Turnover		 2.17 3.12 3.77 3.63 3.66 4.36 4.88 5.03 5.27 6.19 6.93
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 2.47 0.00 0.00 6.03 3.39 3.38 3.13
Days Sales Outstanding (DSO)		 4.65 9.37 2.61 3.78 4.81 22.31 24.44 26.68 26.66 48.97 46.76
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 18.86 0.00 0.00 18.99 25.79 27.24 28.99
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 147.84 0.00 0.00 60.50 107.68 108.02 116.45
Cash Conversion Cycle (CCC)		 4.65 9.37 2.61 3.78 -124.16 22.31 24.44 -14.83 -55.23 -31.82 -40.70
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.27 2.26 2.05 1.63 2.19 2.04 0.80 0.23 1.32 1.02 5.52
Invested Capital Turnover		 -2.43 -2.09 -1.69 -1.55 3.41 2.03 3.08 5.05 2.93 3.56 1.72
Increase / (Decrease) in Invested Capital		 2.98 8.15 9.05 8.89 1.92 -0.22 -1.25 -1.40 -0.86 -1.02 4.72
Enterprise Value (EV)		 72 85 96 99 197 278 248 344 211 207 152
Market Capitalization		 39 43 44 49 135 229 219 300 203 217 153
Book Value per Share		 ($0.67) ($0.77) ($0.92) ($0.83) ($0.66) ($0.23) ($0.13) ($0.16) ($0.03) $0.05 $0.03
Tangible Book Value per Share		 ($0.69) ($0.78) ($0.93) ($0.84) ($0.67) ($0.24) ($0.13) ($0.16) ($0.04) $0.05 $0.03
Total Capital		 25 27 17 24 27 33 48 35 29 34 24
Total Debt		 13 11 10 19 33 25 22 24 25 24 18
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.28
Net Debt		 -12 -14 -4.29 -3.76 7.56 -5.82 -25 -11 -2.68 -9.90 -0.41
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.09 0.00 0.00 0.00 0.22 0.02 0.02
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -4.02 -1.75 -1.71 -2.13 -1.47 -1.42 -1.40 -1.82 -0.70 -0.80 3.63
Debt-free Net Working Capital (DFNWC)		 21 23 13 20 24 30 46 33 27 33 22
Net Working Capital (NWC)		 7.61 12 2.58 1.62 -9.03 4.41 24 8.89 1.98 9.11 4.32
Net Nonoperating Expense (NNE)		 3.06 3.17 4.19 2.88 18 -3.53 2.17 6.46 5.43 2.73 -1.92
Net Nonoperating Obligations (NNO)		 -12 -14 -4.29 -3.76 7.56 -5.82 -25 -11 -2.68 -9.90 -0.41
Total Depreciation and Amortization (D&A)		 0.50 0.23 0.22 0.22 0.22 0.22 0.22 0.21 0.22 0.22 0.23
Debt-free, Cash-free Net Working Capital to Revenue		 -134.86% -46.13% -40.92% -49.10% -35.23% -32.48% -31.73% -38.65% -13.62% -14.64% 66.69%
Debt-free Net Working Capital to Revenue		 695.47% 609.66% 304.97% 465.35% 569.57% 681.35% 1,044.24% 698.81% 529.35% 598.84% 397.63%
Net Working Capital to Revenue		 254.98% 314.92% 61.47% 37.37% -216.44% 101.08% 537.30% 188.82% 38.51% 167.25% 79.44%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.40) ($0.23) ($0.25) ($0.17) ($0.52) ($0.08) ($0.10) $0.01 ($0.17) ($0.08) ($0.03)
Adjusted Weighted Average Basic Shares Outstanding		 45.01M 48.21M 50.37M 50.52M 68.80M 98.99M 108.18M 101.95M 140.10M 183.12M 190.94M
Adjusted Diluted Earnings per Share		 ($0.40) ($0.23) ($0.25) ($0.17) ($0.52) ($0.08) ($0.10) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 45.01M 48.21M 50.37M 50.52M 68.80M 98.99M 108.18M 176.95M 203.07M 203.24M 206.98M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 52.11M 53.99M 59.34M 90.75M 108.19M 108.48M 137.68M 176.95M 203.07M 203.24M 206.98M
Normalized Net Operating Profit after Tax (NOPAT)		 -7.55 -7.83 -8.19 -8.66 -8.74 -7.97 -8.23 -9.81 -8.48 -8.96 -8.59
Normalized NOPAT Margin		 -754.69% -802.70% -698.45% -723.63% -1,055.66% -685.19% -679.71% -652.06% -675.14% -607.92% -714.31%
Pre Tax Income Margin		 -1,060.14% -1,127.56% -1,055.55% -964.16% -3,249.76% -381.69% -858.55% -1,081.52% -1,107.40% -792.88% -555.03%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -58.66 -20.41 -27.56 -1.86 -2,996.11 -757.17 -5,198.50 -3,305.20 -2,328.83 -2,940.00 -6,735.00
NOPAT to Interest Expense		 -42.20 -15.10 -18.77 -2.13 -971.21 -1,328.13 -4,115.65 -1,961.40 -1,413.30 -2,240.18 -8,593.20
EBIT Less CapEx to Interest Expense		 -58.66 -20.41 -27.56 -1.86 -3,006.44 -757.17 -5,198.50 -3,305.20 -2,364.67 -2,945.25 -6,752.00
NOPAT Less CapEx to Interest Expense		 -42.20 -15.10 -18.77 -2.13 -981.54 -1,328.13 -4,115.65 -1,961.40 -1,449.13 -2,245.43 -8,610.20
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Lucid Diagnostics (NASDAQ:LUCD) remains in a high-growth but cash-burning phase. Revenue reached $1.47 million in Q2 2026, up from $1.26 million in Q1 2026 and $1.16 million in Q2 2025. However, revenue remains small relative to the company’s operating cost base, and the company has not yet demonstrated sustainable profitability.

  • Revenue growth improved: Q2 2026 revenue increased approximately 17% sequentially and 27% year over year.
  • Gross margin turned slightly positive: Lucid reported $29,000 of gross profit in Q2 2026, compared with gross losses of $369,000 in Q1 2026 and $400,000 in Q2 2025.
  • Net loss narrowed sequentially: Consolidated net loss improved to $11.7 million in Q2 2026 from $13.9 million in Q1 and $16.3 million in Q4 2025.
  • Cash increased during Q2: Cash and equivalents rose to $33.4 million from $27.9 million at the end of Q1 2026, supported by $16.8 million of financing inflows.
  • Liquidity improved from early 2025: Cash increased from $25.2 million at the end of Q1 2025 to $33.4 million in Q2 2026, although much of the improvement came from equity financing.
  • Current liquidity is limited but positive: Current assets of $36.6 million exceeded current liabilities of $27.5 million, producing a current ratio of approximately 1.3.
  • Operating expenses remain elevated: Selling, general and administrative expense was $5.8 million, marketing expense was $5.8 million, and research and development expense was $1.2 million in Q2 2026.
  • Operations continue to consume substantial cash: Operating cash flow was negative $11.3 million in Q2 2026, following negative operating cash flow of $12.1 million in Q1 2026. Operating cash flow has been negative in every reported quarter provided.
  • Lucid remains deeply unprofitable: Operating loss was $12.8 million in Q2 2026, while net loss attributable to common shareholders was $14.7 million, or $0.08 per share.
  • Financing and dilution remain major risks: The company issued $16.8 million of common equity in Q2, while weighted-average basic shares increased to 183.1 million from 140.1 million in Q1. Short-term debt also remained high at $23.5 million.

The most notable improvement is at the gross-profit level. After reporting gross losses in several recent quarters, Lucid generated a small positive gross profit in Q2 2026. Revenue has also generally trended higher, rising from $783,000 in Q3 2023 to $1.47 million in Q2 2026. Nevertheless, the company’s operating expenses are nearly nine times its quarterly revenue, leaving a substantial gap to profitability.

Cash-flow trends remain the primary concern for investors. Q2 operating cash burn of $11.3 million was only partially offset by $16.8 million of equity financing, resulting in a $5.5 million increase in cash. At the current quarterly operating burn rate, the $33.4 million cash balance provides less than one year of operating funding before considering debt repayments, changes in working capital, or additional investment needs. Continued equity issuance could support operations but may further dilute existing shareholders.

The balance sheet is mixed. Total equity was positive at $10.9 million at June 30, 2026, but retained earnings were negative $312.7 million, reflecting accumulated losses. Accounts receivable increased to $1.1 million from $689,000 in Q1, while prepaid expenses declined to $1.6 million from $2.3 million. Investors should also note that several historical statements in the supplied data are marked as restated or calculated, so quarter-to-quarter comparisons may be affected by accounting revisions.

11/13/26 09:45 AM ETAI Generated. May Contain Errors.

Lucid Diagnostics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Lucid Diagnostics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Lucid Diagnostics' net income appears to be on a downward trend, with a most recent value of -$58.01 million in 2025, falling from -$8.28 million in 2020. The previous period was -$45.53 million in 2024. Find out what analysts predict for Lucid Diagnostics in the coming months.

Lucid Diagnostics' total operating income in 2025 was -$49.64 million, based on the following breakdown:
  • Total Gross Profit: -$1.96 million
  • Total Operating Expenses: $47.68 million

Over the last 5 years, Lucid Diagnostics' total revenue changed from $0.00 in 2020 to $4.71 million in 2025, a change of 470,600,000.0%.

In the past 12 quarters, Lucid Diagnostics' cash and equivalents has ranged from $14.49 million in Q3 2024 to $47.33 million in Q3 2025, and is currently $17.99 million as of their latest financial filing in Q3 2026.

Lucid Diagnostics had total debt of $24 million at the end of 2025, a 29.0% increase from 2024, and none in 2020.

Over the last 5 years, Lucid Diagnostics' book value per share changed from -0.96 in 2020 to -0.16 in 2025, a change of 83.6%.


Related Companies

Financial statements for NASDAQ:LUCD last updated on 11/12/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...
Base Camp Trading | Sponsoredtc pixel
Trump’s EO to send this $5 stock ripping higher…?
President Trump's December executive order declared space a national security and economic priority, fueling a...
Traders Agency | Sponsoredtc pixel
Today's free pick (on me)
Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...
Behind the Markets | Sponsoredtc pixel
Trump compared today's market to 1929
President Trump warned of a 1929-style depression if Democrats won control of Congress. On November 3, they di...
USA Capital Gold | Sponsoredtc pixel
Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...
Porter & Company | Sponsoredtc pixel
URGENT: If you own a home, please review the map below.
More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...
Paradigm Press | Sponsoredtc pixel
Uranium Mine Flood That Sparked a 2006 Price Surge Returns
In 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...
Digest Publishing | Sponsoredtc pixel